Scientific Director

Professor Falkenberg holds German and international patents in the fields of bioreactor technology, tumor immunology and nephrotoxicity testing. In 2001 he founded CIRES: Cell & Immune Research Services GmbH, a biotech contract research company in Dortmund. In 2011 he co-founded CyTuVax.

Professor Falkenberg received his MSc in Biochemistry at the J.W. Goethe Universität in Frankfurt/Main and his PhD in Biochemistry at the Department of Biochemistry (Faculty of Chemistry) of the Ruhr-Universität Bochum. He was Postdoc fellow at the Department of Chemical Immunology of the Weizmann Institute of Science in Rehovot, Israel from 1971 – 1973. In 1981, he was privat lecturer at the Department of Medical Microbiology, Medical Faculty of the Ruhr-Universität Bochum. In 1986 he became Professor of Immunology in the Medical Faculty of the Ruhr-Universität Bochum.

Prof Falkenberg’s main scientific interests are immunogenetics, cellular immunology, tumor immunology, cell culture, and bioreactor technology. For the last 15 years, Prof. Falkenberg’s main work was to develop the CyTuVax’s adjuvant platform technology.